Canurta Pipeline
| Drug | Indication | Phase |
|---|
| CNR-401 | Amyotrophic Lateral Sclerosis (ALS) | Preclinical (Phase 1 planned 2026) |
| CNR-100 | Chronic Inflammatory Diseases (e.g., rheumatoid arthritis) | Preclinical |
| CNR-400 | Neurodegenerative Disorders (e.g., Alzheimer’s, FTD) | Preclinical |